There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 pg/g wet weight) and approximated levels found in lead workers (30 pg/g ). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-rayinduced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies.
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Exposure Levels in Adults
The role of environmental lead in the induction of hypertension and renal disease in adults has received little attention since measurements in the nineteenth century first suggested a relationship between lead, high blood pressure, and disease of the kidneys (1). There is now considerable evidence that excessive lead absorption causes slowly progressive renal disease and that lead predisposes individuals to hypertension even in the absence of detectable renal failure.
The health effects of lead in adults has gone largely unrecognized because of conventional reliance on the blood lead measurement (PbB) using criteria for normal based on symptomatic acute poisoning. Over 90% of the body burden of lead is stored in bone and has a biological half-life approximating several decades (2) . Cumulative lead absorption is best assessed at present by the EDTA lead mobilization test (3) . The 2000 years. In adult lead workers, transient hypertension is common during the acute phase. In children, the kidneys leak amino acids and other circulating substances normally reabsorbed by the proximal tubule (Fanconi syndrome). Blood lead levels are more than 70 ,ug/dL during the acute episode. Symptoms are reversed by chelation therapy or termination of exposure.
Chronic Industrial Exposure
Continuous lead absorption at levels insufficient to produce the hallmarks of acute intoxication, increases the body burden of lead and can induce hypertension, interstitial nephritis, and behavioral abnormalities after a few years. Blood lead levels depend on the proximity to recent exposure and may be only modestly elevated at the time clinical symptoms are recognized; PbB is from 30 to 80 gg/dL. Nonoccupationally exposed adult males have mean PbB levels of about 15 ,ug/dL (4). Prolonged exposure in the workplace produces bone lead stores that are more than four times that of nonoccupationally exposed individuals. Transiliac bone biopsy lead levels averaged 30 gg/g in 22
Belgian lead workers (5) . The mean chelatable lead in these men was 1923 ig/3 days. In individuals without unusual exposure, transiliac bone lead levels averaged 6 jg/g.
Sporadic Exposure
Increased total body lead burdens result from intermittent (usually unrecognized) exposure in the absence of symptoms of acute intoxication. Sporadic high (Table 2) . Chelatable lead was also higher in hypertenon blood pressure is the subject of other papers in this sives with renal failure than in control patients with meeting. Universal exposure makes it difficult to comparably diminished renal function due to another identify appropriate control groups. Consequently, the identifiable etiology (440 ± 50 ,ug/3 days). The control generally accepted upper limit of normal for the EDTA renal failure group demonstrates that renal failure per lead mobilization test (650 ,ug lead chelate/day) is se does not increase mobilizable lead. Moreover, the undoubtedly too high. Clinical studies of small groups known duration of hypertension in the patients with to detect the role of lead in hypertension are, therefore, renal failure (7 years) was half of that of hypertensives likely to be unproductive. with preserved renal function (14 years). The in- creased duration of elevated pressure in patients without renal failure indicates that hypertension was not the cause, but the result of renal disease. Although these patients had been considered to have essential hypertension prior to chelation testing, the study indicates that lead played an etiologic role in the development of hypertension and renal failure in some.
This interpretation is founded on the assumption that the accessibility of bone lead stores to the chelating agent is essentially equivalent in hypertensive and control renal failure patients. Studies recently performed in DeBroe's laboratory at the University of Antwerp support this view (5) . One hundred fiftythree transiliac bone biopsies obtained for aluminum studies from patients with end-stage renal disease were analyzed for lead and calcium. The mean bone lead in these dialysis patients was 6 ,ug/g, indicating that bone lead is not elevated by end-stage renal disease and that the increased mobilizable lead in hypertensives with renal failure is, therefore, not due to increased lead storage induced by renal failure. Moreover, patients with analgesic nephropathy, a form of interstitial nephritis that can be accurately diagnosed, had low levels of iliac lead (mean = 4 gg/g). Interstitial nephritis therefore does not appear to induce a unique form of uremic osteodystrophy characterized by increased bone lead stores.
Five percent of the French, German, and Belgium dialysis patients studied in Belgium had iliac bone lead levels comparable to those found in lead workers: 20 tg/g wet weight. Bone histomorphometry in the dialysis patients with elevated bone leads did not differ from that in dialysis patients with low bone leads confirming the absence of unique bone disease. These data suggest that up to 5% of the European dialysis population have unsuspected excessive lead absorption as the cause, or contributing cause, of their end-stage renal disease (5) .
Additional studies of 24 Belgian lead workers demonstrated that the chelation test provides a good estimate of bone lead. The lead content of transiliac bone biopsies compared to the EDTA lead mobilization test gave a linear regression correlation coefficient (r) of 0.87. Taken together, these studies provide criteria for the diagnosis of excessive cumulative lead absorption directly from bone biopsies, which may prove useful in functionally anephric patients.
Evidence was also obtained in Antwerp indicating that measurement of the Pb:Ca ratio in bone is more reliable than the absolute bone lead concentration. Bone Pb:Ca shows less variability than the [Pb] , presumably because of the variable quantity of noncortical bone in the biopsy specimens. In addition, the effect of demineralization due to uremic osteodystrophy is minimized when the Pb:Ca ratio is used.
The Pb:Ca ratio has another advantage. It is precisely Pb:Ca that is most accurately measured by the new technique of in vivo tibial X-ray induced X-ray fluorescence (XRF) using characteristic K X-rays from lead, elicited by a 109Cd radioactive source (7, 8) . This technique for assessing bone lead content eliminates the need for injecting EDTA and for urine collections and thus is a more practical diagnostic tool particularly for epidemiologic studies. The main limitation of XRF using K fluorescent X-rays may be the difficulty in measuring bone lead levels encountered in the normal population (< 10 ,ug/g). XRF can detect bone lead levels of 20 ,ug/g or higher with good precision and therefore is suitable for detecting individuals at risk from industrial level lead absorption.
In 21 unselected renal patients from New Jersey tibial lead (determined by in vivo XRF) and chelatable lead levels fell within the expected range (95% confidence limits) found by direct transiliac bone biopsy in the 24 patients from Antwerp who had EDTA lead mobilization tests (Fig. 1) . XRF therefore appears to be suitable for determining the risk of renal disease in the general population and in dialysis patients, an undertaking that is essential for public health planning.
These studies provide insight into the question: How much lead is too much? The normal population has an iliac lead concentration of about 5 ,ug/g compared to > 20 ,ug/g in lead workers. A fourfold increased in bone lead in occupational as compared to ambient exposure has also been reported by Barry (3) . Thus, a fourfold increase in lead absorption places an individual at the same risk as the lead worker for lead-induced hypertension, renal disease, and behavioral abnormalities. The total body lead of a 70-year-old man (whose bone lead is 5 ,ug/g) approximates 200 mg (9,10). Consequently, the absorption of 500 jg excess Pb per day for 5 years (182 mg/year) turns a normal body lead burden into that of an industrial lead worker. Such absorption can easily be acquired from lead leached from ceramics, from contaminated water, or from pulverized old lead paint chips. Current FDA regulations permit 5 
